Fundraising Fox

HYKU Biosciences

Burlington, US · Founded 2021 · Delaware corporation · 4 known investors

hykubiosciences.com ↗

Hyku Biosciences develops covalent medicines to improve patient outcomes by advancing the scientific boundaries of this therapeutic approach. The company serves patients and the pharmaceutical industry.

BiotechDeep TechMedical Devicesin /hyku-biosciences

Founders & leadership

JG
JOHN GUSTOFSONDirector
LT
LAURA TADVALKARDirector
KC
KLEEM CHAUDHARYExecutive Officer, Director, Promoter
MV
MATTHIAS VAN WOENSELDirector
KC
Kleem Chaudhary, PhDPresident & CEO
K(
Ku-Lung (Ken) Hsu, PhDEndowed Associate Professor of Chemistry
LB
LAURA BRASSDirector

Investors · 4

Droia Ventures✓ verifiedLeuven · $540Kvia Matthias Van Woensel · board
Eisai Innovation, Inc.✓ verifiedSan Francisco
Novartis Venture Fund✓ verifiedBasel · $5M – $25M
RA Capital✓ verifiedBoston

Reported raises · per SEC filings

Form D private placements
▶$6.6MraisedJan 2026 · 8 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • JOHN GUSTOFSONDirector
  • LAURA BRASSDirector
  • LAURA TADVALKARDirector
  • KLEEM CHAUDHARYExecutive Officer, Director, Promoter
  • MATTHIAS VAN WOENSELDirector
Offering amount
$21M
Amount sold
$6.6M
First sale
Dec 2025
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.